HR-4623-119
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Nikema Williams (D-GA)
What it does
This bill would require the Secretary of Health and Human Services, through the Centers for Medicare & Medicaid Services (CMS), to issue regulations within one year mandating that direct-to-consumer television advertisements — including broadcast, cable, streaming, and satellite — for prescription drugs and biological products covered by Medicare or Medicaid include a text statement showing the list price for a typical 30-day supply or course of treatment. The bill would also direct CMS to determine whether the requirement should extend to other advertising formats, how the price disclosure should be formatted, and what enforcement mechanisms should apply.
Who benefits
Patients with Medicare or Medicaid coverage who would gain clearer price information before discussing drugs with their doctors. Uninsured or underinsured consumers who pay closer to list price and would benefit from upfront cost transparency. Generic and biosimilar drug manufacturers whose lower-cost alternatives may appear more attractive by comparison. Patient advocacy organizations focused on drug pricing transparency. Physicians and pharmacists who may receive better-informed patients. Taxpayers and federal programs if transparency creates indirect downward pricing pressure.
Who is hurt
Brand-name pharmaceutical and biologic manufacturers whose high list prices would be prominently displayed, potentially reducing consumer demand for their advertised products. Advertising and marketing agencies that produce drug commercials and may face increased production costs or creative constraints. Broadcasters and streaming platforms that air drug ads and could see reduced advertiser spending if manufacturers pull TV campaigns. Patients with insurance who pay far less than list price and may be confused or alarmed by a list price that does not reflect their actual out-of-pocket cost. Small or regional TV stations that depend heavily on pharmaceutical advertising revenue.
Supporters argue
Supporters argue that consumers deserve to know the cost of a drug before asking their doctor about it, and that list prices — often thousands of dollars per month — are a meaningful signal of a drug's cost burden on the healthcare system. They contend that a near-identical CMS rule issued in 2019 was struck down not on policy grounds but on procedural ones, demonstrating bipartisan appetite for this type of transparency. They further argue that informed patients make better healthcare decisions, and that price visibility may create market pressure that moderates list prices over time.
Opponents argue
Opponents argue that list prices are rarely what patients actually pay — after insurer negotiations and manufacturer rebates, actual costs can be dramatically lower — meaning mandatory list price disclosures may mislead rather than inform consumers. They contend that the First Amendment limits the government's ability to compel commercial speech, and that requiring specific price statements in ads could face legal challenge under the standard that compelled disclosures must be "purely factual and uncontroversial." They also argue that manufacturers may simply pull TV advertising rather than comply, reducing patient awareness of treatment options without meaningfully lowering drug costs.
Constitutional context
Congress's authority to regulate drug advertising flows from the Commerce Clause (Art. I, §8, cl. 3), and the bill conditions the requirement on Medicare/Medicaid coverage, grounding it in the Taxing and Spending Clause (Art. I, §8, cl. 1). A compelled disclosure requirement in commercial advertising may also raise First Amendment questions, though the Supreme Court has generally permitted factual, non-misleading disclosure mandates in commercial speech contexts. Post-Loper Bright (2024), courts will independently review whether CMS's implementing regulations stay within the bill's statutory boundaries rather than deferring to the agency's interpretation.
Checks and balances
The Executive Branch (HHS/CMS) gains rulemaking authority to define format, scope, and enforcement; Congress retains oversight through appropriations and committee review, and federal courts may review CMS regulations under the post-Loper Bright independent-judgment standard.
Historical precedent
A CMS rule issued in 2019 under the Trump administration required list price disclosures in drug TV ads, but a federal district court struck it down in Merck v. U.S. Department of Health and Human Services (D.D.C. 2019), finding CMS lacked statutory authority — a procedural deficiency this bill attempts to remedy by providing explicit congressional authorization.